Navigation Links
QRxPharma Announces Interim Analysis of Final Pivotal Phase 3 Study for MoxDuo®IR
Date:9/1/2010

analgesic effects of flexible dose versus fixed low dose of MoxDuo IR over a 48 hour study period. Since the blinded interim analysis was based on how much variability was observed when both dosage groups were combined and did not evaluate the magnitude of the difference between the two treatment groups per se, one must be cautious in drawing conclusions that the expected endpoints will be met. This type of interim analysis conducted for the purpose of sample size re-estimation, which was accepted by the FDA, does not result in a statistical penalty in the p-values of the final analysis to be conducted upon study completion.For more information please contact:Dr John W HoladayManaging Director and Chief Executive OfficerTel: +1 301 908 3086Email: john.holaday@qrxpharma.comChris J CampbellChief Financial Officer and Company SecretaryTel: +61 2 9492 8021Email: chris.campbell@qrxpharma.comForward Looking StatementsThis release contains forward-looking statements. Forward-looking statements are statements that are not historical facts; they include statements about our beliefs and expectations. Any statement in this release that states our intentions, beliefs, expectations or predictions (and the assumptions underlying them) is a forward-looking statement. These statements are based on plans, estimates and projections as they are currently available to the management of QRxPharma. Forward-looking statements therefore speak only as of the date they are made, and we undertake no obligation to update publicly any of them in light of new information or future events. By their very nature, forward-looking statements involve risks and uncertainties. A number of important factors could therefore cause actual results to differ materially from those contained in any forward-looking statement. Such factors include risks relating to the stage of products under development; uncertainti
'/>"/>
SOURCE QRXPharma
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. QRxPharma Doses First Patients in Phase III Clinical Trial Program for its Dual Opioid Pain Therapy
2. QRxPharma Releases Successful Phase 3 Study Results for Dual Opioid Pain Therapy
3. QRxPharma Releases Additional Phase 3 Data for Q8003IR Dual Opioid Pain Therapy
4. QRxPharma Successfully Completes Comparative Study for Dual-Opioid(TM) Pain Therapy
5. QRxPharma Inks Deal with Patheon for the Manufacture of MoxDuo(TM)CR
6. QRxPharma Limited Announces A$21.6 Million Fully Underwritten Capital Raising
7. QRxPharma Initiates Second Pivotal Phase 3 Study of MoxDuo(TM)IR Dual-Opioid(TM) for NDA Submission
8. QRxPharma Limited and China Aoxing Pharmaceutical Company Announce Strategic Alliance for Development of MoxDuo(R)IV
9. QRxPharma Releases Additional Pivotal Phase 3 Combination Rule Study Data for MoxDuo(R)IR in Patients with Post-Surgical Pain
10. QRxPharma Successfully Completes Comparative Phase 1 Proof-of-Concept Study for MoxDuo(R) CR Tablet Formulation
11. QRxPharma Receives Positive Feedback from Scientific Advice Meetings in Europe on MoxDuo®IR Development and Registration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR ... JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF ... ABBV ) today announced financial results for the ... was another very strong quarter for AbbVie, as we delivered ... announced plans to merge with Shire, a strategic action that ...
(Date:7/25/2014)... -- Dr. Michael Gabriel of a prominent ... recent study, which shows how grief in pregnancy may cause ... According to US News , "Unborn ... than others to grow up overweight or obese, even if ... two specific types of stress that caused obesity: "Children whose ...
(Date:7/24/2014)... July 24, 2014  Parnell Pharmaceuticals Holdings Ltd ... will be added to Parnell,s already extensive pipeline ... Ltd, a biotechnology company. The compounds now known ... promise in bone regeneration and dermal regeneration, respectively. ... compounds for the veterinary market with the potential ...
Breaking Medicine Technology:AbbVie Reports Second-Quarter 2014 Financial Results 2AbbVie Reports Second-Quarter 2014 Financial Results 3AbbVie Reports Second-Quarter 2014 Financial Results 4AbbVie Reports Second-Quarter 2014 Financial Results 5AbbVie Reports Second-Quarter 2014 Financial Results 6AbbVie Reports Second-Quarter 2014 Financial Results 7AbbVie Reports Second-Quarter 2014 Financial Results 8AbbVie Reports Second-Quarter 2014 Financial Results 9AbbVie Reports Second-Quarter 2014 Financial Results 10AbbVie Reports Second-Quarter 2014 Financial Results 11AbbVie Reports Second-Quarter 2014 Financial Results 12AbbVie Reports Second-Quarter 2014 Financial Results 13AbbVie Reports Second-Quarter 2014 Financial Results 14AbbVie Reports Second-Quarter 2014 Financial Results 15AbbVie Reports Second-Quarter 2014 Financial Results 16AbbVie Reports Second-Quarter 2014 Financial Results 17AbbVie Reports Second-Quarter 2014 Financial Results 18AbbVie Reports Second-Quarter 2014 Financial Results 19AbbVie Reports Second-Quarter 2014 Financial Results 20AbbVie Reports Second-Quarter 2014 Financial Results 21AbbVie Reports Second-Quarter 2014 Financial Results 22AbbVie Reports Second-Quarter 2014 Financial Results 23AbbVie Reports Second-Quarter 2014 Financial Results 24AbbVie Reports Second-Quarter 2014 Financial Results 25AbbVie Reports Second-Quarter 2014 Financial Results 26AbbVie Reports Second-Quarter 2014 Financial Results 27AbbVie Reports Second-Quarter 2014 Financial Results 28AbbVie Reports Second-Quarter 2014 Financial Results 29AbbVie Reports Second-Quarter 2014 Financial Results 30AbbVie Reports Second-Quarter 2014 Financial Results 31AbbVie Reports Second-Quarter 2014 Financial Results 32AbbVie Reports Second-Quarter 2014 Financial Results 33AbbVie Reports Second-Quarter 2014 Financial Results 34AbbVie Reports Second-Quarter 2014 Financial Results 35AbbVie Reports Second-Quarter 2014 Financial Results 36
(Date:7/26/2014)... Earlier this week, the big announcement that fans of music was ... iHeartRadio Music Festival on Sept. 19 and 20 from the ... of music will have an act they are excited to see ... of Taylor Swift, as well as Zac Brown Band and Eric ... Grande, and Iggy Azalea, while R&B fans will be excited to ...
(Date:7/26/2014)... gas chromatography reagents report defines and segments the concerned market ... chromatography reagents market in Europe is valued at $ 314.8 ... $445.5 million by 2018, at a CAGR of 8.6 %, ... the European gas chromatography reagents market, to get an idea ... glimpse of the segmentation of gas chromatography reagents market in ...
(Date:7/26/2014)... 26, 2014 As reported by ... changing based on 3 factors: smaller spaces, multi-generational access, ... bathroom trend of 2014 lists, including this article ... Amerec , a leading manufacturer of steam bath ... largely due to smaller spaces and an effort to ...
(Date:7/26/2014)... New York, New York (PRWEB) July 26, 2014 ... continue to be filed in U.S. courts, Bernstein ... calling on federal health regulators to ban uterine morcellation. ... individuals include a 46-year-old mother of four from California ... of uterine cancer called leiomyosarcoma just 10 days after ...
(Date:7/26/2014)... July 26, 2014 We’ve all ... the playing field; however, concussions in the workplace ... occupations with the highest risk of head injury ...     Firefighters ,     Police officers ,     Race ...     Delivery personnel , “Most ...
Breaking Medicine News(10 mins):Health News:iHeartRadio Music Festival Tickets in Las Vegas at MGM Grand Garden Arena: Ticket Down Slashes Ticket Prices on the iHeart Radio Music Festival for Sept. 19 & 20th 2Health News:iHeartRadio Music Festival Tickets in Las Vegas at MGM Grand Garden Arena: Ticket Down Slashes Ticket Prices on the iHeart Radio Music Festival for Sept. 19 & 20th 3Health News:Europe Gas Chromatography Reagents Market is Expected to Reach $445.5 million in 2018 - New Report by MicroMarket Monitor 2Health News:Europe Gas Chromatography Reagents Market is Expected to Reach $445.5 million in 2018 - New Report by MicroMarket Monitor 3Health News:Europe Gas Chromatography Reagents Market is Expected to Reach $445.5 million in 2018 - New Report by MicroMarket Monitor 4Health News:Europe Gas Chromatography Reagents Market is Expected to Reach $445.5 million in 2018 - New Report by MicroMarket Monitor 5Health News:Amerec Finds Bathroom Design Trends Change Based on Water Consumption and Other Factors 2Health News:Morcellator Lawsuit News: Bernstein Liebhard LLP Notes New Calls for Ban on Uterine Mocellation In Light of Cancer Risk 2Health News:Morcellator Lawsuit News: Bernstein Liebhard LLP Notes New Calls for Ban on Uterine Mocellation In Light of Cancer Risk 3Health News:Morcellator Lawsuit News: Bernstein Liebhard LLP Notes New Calls for Ban on Uterine Mocellation In Light of Cancer Risk 4Health News:KORT Physical Therapists Take the Mystery Out of Identifying and Treating Workplace Head Injuries 2Health News:KORT Physical Therapists Take the Mystery Out of Identifying and Treating Workplace Head Injuries 3
... targeted searches to ob/gyn specialty-specific ... patient care and practice management, ... (http://www.OBGManagement.com ), a leader in the field of obstetrics ... latest search engine tool: OBGfindit.com (http://www.OBGfindit.com )., ...
... discovered a new perspective in the study of infectious ... looking at an organism and how it works within ... published in Environmental Microbiology, Dr Carla Pruzzo, Dr Luigi ... bacteria and its interaction with the environment and found ...
... Sharp Rise in Gonorrhea Cases, HARRISBURG, Pa., May 2 ... of Gonorrhea last year in Delaware County,the Pennsylvania Department of ... and 24 be routinely screened for the,disease, as well as ... to 921 in 2007 from 513,the year before., Of ...
... (Nasdaq:,WBMD) and HLTH Corporation (Nasdaq: HLTH ) today ... the Third Annual Needham & Company,Internet & Digital Media ... ET., Investors, analysts and the general public are ... presentation over the Internet. The broadcast,can be accessed at ...
... Lupus Foundation of,America joins a coalition of approximately 100 ... May 10. More than 1.5 million,Americans and at least ... struggle daily with the often-debilitating health,consequences of the chronic ... an unbalanced immune system that can become,destructive to any ...
... DIEGO, May 2 /PRNewswire-USNewswire/ - It is the cosmetic ... from their hips and thighs and,redistributing it to their ... or effective. Fat grafting for breast enhancement will be,discussed ... American Society,for Aesthetic Plastic Surgery (ASAPS) being held at ...
Cached Medicine News:Health News:OBGManagement.com and Convera(R) Launch Search Site for Physicians in the ObGyn Specialty 2Health News:Lupus Organizations Issue International Call-to-Action to Combat Disease Affecting Five Million People 2Health News:Breast Enhancement With Fat: Pros and Cons 2Health News:Breast Enhancement With Fat: Pros and Cons 3
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: